| Summary: | The aim of this study is to evaluate prognostic and therapeutic implications of microvessel density (MVD) in the recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) in prostate cancer (PCa). As of April 2019, EMBASE, PubMed, Cochrane Library, Science Direct/Elsevier, MEDLINE, and CNKI are used for systematic literature retrieval to investigate the correlation between MVD and PCa. Meta-analysis was performed using Review Manager and Stata software. Combined hazard ratio (HR) was identified with 95% confidence intervals (95% CI) in a random or fixed effects model. Thirteen studies were identified in this article. Of which, 8 studies analyzed for the recurrence-free survival (2,399 patients) demonstrated that MVD significantly elevated in the poor recurrence-free survival (HR 2.57, 95% CI 2.21–2.97). Other 2 eligible studies (330 patients) with 3 data sets for the MVD-OS analysis and the pooled HR (HR 1.70, 95% CI 1.27–2.28) suggested a weak risk of overall death rate in patients with high-MVD levels. The last 3 studies for disease-specific survival (220 patients) suggested that the association with high MVD and disease-specific survival may not have statistically significance (HR 1.32, 95% CI 0.49–3.56). This study suggests that high intratumoral MVD appears a significant progenitor for poor recurrence-free survival of PCa.
|
|---|
